Table 1 Baseline characteristics of all patients according to advanced lung cancer inflammation index (ALI) at the time of diagnosis.

From: Clinical significance of the advanced lung cancer inflammation index in patients with limited-stage small cell lung cancer treated with chemoradiotherapy

Variables

All patients (N = 87)

ALI < 44.3 (N = 48)

ALI ≥ 44.3 (N = 38)

P-values

Sex

   

0.6151

 Male

75 (86.2)

40 (16.7)

34 (89.5)

 

 Female

12 (13.8)

8 (83.3)

4 (10.5)

 

Age, years (mean ± SD)

64.7 ± 8.9

65.1 ± 10.1

64.4 ± 7.3

0.7437

BMI, kg/m2 (mean ± SD)

23.6 ± 3.3

22.7 ± 3.0

24.8 ± 3.3

0.0019

Smoking, ever-smoker

85 (97.7)

47 (97.9)

37 (97.4)

1.0000

Years of initiation for radiotherapy

0.8914

 2005–2009

14 (16.1)

7 (14.6)

7 (18.4)

 

 2010–2014

28 (32.2)

16 (33.3)

12 (31.6)

 

 2015–2019

45 (51.7)

25 (52.1)

19 (50.0)

 

Radiotherapy dose (Gy)

   

1.0000

 45 ≤  < 60

42 (48.3)

23 (47.9)

19 (50.0)

 

 ≥ 60

45 (51.7)

25 (52.1)

19 (50.0)

 

ECOG PS

   

0.7616

 0

43 (49.4)

23 (47.9)

20 (52.6)

 

 1

40 (46.0)

22 (45.8)

17 (44.8)

 

 2

4 (4.6)

3 (6.3)

1 (2.6)

 

COPD

42 (48.3)

25 (52.1)

16 (42.1)

0.4823

Diabetes

30 (34.5)

19 (39.6)

11 (28.9)

0.4237

Hypertension

36 (41.4)

18 (37.5)

17 (44.7)

0.6474

Chronic kidney disease

17 (19.5%)

11 (22.9%)

6 (15.8%)

0.5812

TNM stage

   

0.1338

 I

4 (4.6)

1 (2.1)

3 (7.9)

 

 II

12 (13.8)

4 (8.3)

8 (21.1)

 

 IIIA

30 (34.5)

16 (33.3)

13 (34.2)

 

 IIIB/IIIC

41 (47.1)

27 (56.3)

14 (36.8)

 

Schedule of radiotherapy

   

1.0000

 Sequential

11 (12.6)

6 (12.5)

5 (13.2)

 

 Concurrent

76 (87.4)

42 (87.5)

33 (86.8)

 

Chemotherapy regimen

   

0.3008

 Etoposide + cisplatin

61 (70.1)

30 (62.5)

30 (78.9)

 

 Etoposide + carboplatin

22 (25.3)

15 (31.2)

7 (18.4)

 

 Others*

4 (4.6)

3 (6.2)

1 (2.6)

 

Prophylactic cranial irradiation

35 (40.2)

18 (37.5)

17 (44.7)

0.6474

Consolidation chemotherapy

30 (34.5)

13 (27.1)

16 (42.1)

0.2173

Laboratory findings (mean ± SD)

 WBC

7487.9 ± 1963.9

7707.3 ± 2124.9

7157.9 ± 1716.3

0.1993

 ALC

1901.8 ± 680.4

1555.9 ± 541.0

2346.1 ± 586.6

 < 0.0001

 ANC

4619.2 ± 1664.8

5114.1 ± 1809.3

3928.1 ± 1142.9

0.0006

 NLR

2.8 ± 1.6

3.7 ± 1.7

1.7 ± 0.4

 < 0.0001

 Albumin (n=86)

4.1 ± 0.4

4.0 ± 0.4

4.2 ± 0.3

0.0430

  1. *Others included combining regimens including irinotecan and cisplatin. SD: standard deviation; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group Performance Status; WBC: white blood cell; ALC: absolute lymphocyte count; ANC: absolute neutrophil count; NLR: neutrophil to lymphocyte ratio.
Back to article page